PD-1 Blockade in Non-Small Cell Lung Cancer
Demographics (2)
- Age - Patient's age (phv00253415.v1.p1)
- Sex - Gender of participant (phv00253416.v1.p1)
Disease Events (11)
- AFFECTION_STATUS - Case control status of the subject. All subjects are patients with non-small cell lung cancer. (phv00252805.v1.p1)
- Durable_Clinical_Benefit - Patient's clinical benefit (phv00253425.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00252815.v1.p1)
- IS_TUMOR - Tumor status (phv00252814.v1.p1)
- PD-L1 - Programmed death-ligand 1 (PD-L1) expression (phv00253419.v1.p1)
- PFS (mos) - Progression free survival in months (phv00253423.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00252816.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00252817.v1.p1)
- Resp - Denotes best overall response to pembrolizumab (phv00253424.v1.p1)
- TUMOR_STAGE - Tumor stage of sample (phv00252818.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00252820.v1.p1)
Substance Use (2)
- Pack-years - Product of number of packs per day and number of years smoked (phv00253418.v1.p1)
- Smoking - Self-reported smoking status (phv00253417.v1.p1)
Other (21)
- ANALYTE_TYPE - Analyte Type (phv00252813.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00252812.v1.p1)
- Cohort - Patient's cohort in current study (phv00253413.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00252802.v1.p1)
- Dose (mg/kg) - Dose (mg/kg) (phv00253421.v1.p1)
- GENOTYPING_CENTER - Name of the center which conducted genotyping (phv00252821.v1.p1)
- Histology - Tumor histology (phv00253414.v1.p1)
- Priors - Prior courses of cytotoxic chemotherapy. Combination chemotherapy counted as a single course. No patient had received prior immunotherapy. (phv00253420.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00252811.v1.p1)
- SAMPLE_ID - Sample ID (phv00252807.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00252808.v1.p1)
- SAMPLE_USE - Sample use. Seq_DNA_SNP_MAF_Sum: Samples were used to generate aggregate mutation annotation file (.maf); Seq_DNA_WholeExome: Whole exome sequencing (phv00252810.v1.p1)
- Sched - Pembrolizumab dosed every 2 or 3 weeks as indicated. (phv00253422.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00252822.v1.p1)
- Smoking_Signature - Molecular smoking signature (phv00253426.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00252809.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00252804.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00253412.v1.p1)
- SUBJECT_ID - Subject ID (phv00252801.v1.p1)
- SUBJECT_ID - Subject ID (phv00252806.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00252803.v1.p1)